Literature DB >> 17936228

Hepatitis C virus core protein enhances B lymphocyte proliferation.

A Alisi1, C Giannini, A Spaziani, S Anticoli, P Caini, A L Zignego, C Balsano.   

Abstract

HCV chronic infection leads to liver diseases and also to a wide range of extrahepatic disorders including benign, but pre-lymphomatous forms (mixed cryoglobulinemia) to frank hematological neoplasia (non-Hodgkin's lymphoma). Recent data showed the involvement of p53 superfamily members in the pathogenesis of different lymphatic malignancies. In fact, tymomas and a subset of non-Hodgkin's lymphomas (NHLs) express high levels of p63. Thus, we analyzed whether alterations in p53 superfamily gene expression are observable in B lymphocytes isolated from HCV-infected patients with and without lymphoproliferative disorders. We showed, by real-time PCR, a significant induction of DNp63 mRNAs in B lymphocytes obtained from HCV-positive low grade non-Hodgkin's lymphoma patients. Since our current understanding of HCV proteins emphasizes the ability of the HCV core protein to deregulate the expression and activity of p53-related proteins, we established different B lymphocyte cell lines (Wil2-ns, Daudi and Ramos) stably expressing HCV core protein, in order to investigate the possible involvement of the viral protein in the upregulation of DNp63 in B lymphocytes. The analysis of p63 family transcripts showed no transcriptional changes for the p63 TA isoforms, whereas an increase (>5 times) of DNp63 mRNA occurred. In all cell lines, this abnormal expression was associated with a significant increase of cell proliferation that was specifically inhibited by silencing DNp63 mRNA. These findings suggest a pathogenetic role of the HCV core in HCV-related lymphomagenesis, through the induction of DNp63's pro-proliferative effects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17936228     DOI: 10.1016/s1590-8658(07)80015-6

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  5 in total

1.  Impact of DAA-Based Regimens on HCV-Related Extra-Hepatic Damage: A Narrative Review.

Authors:  Evangelista Sagnelli; Caterina Sagnelli; Antonio Russo; Mariantonietta Pisaturo; Clarissa Camaioni; Roberta Astorri; Nicola Coppola
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Hepatitis C virus lymphotropism and peculiar immunological phenotype: effects on natural history and antiviral therapy.

Authors:  Paolo Conca; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2009-05-21       Impact factor: 5.742

3.  Long-term serologic follow-up of isolated hepatitis B core antibody in HIV-infected and HIV-uninfected women.

Authors:  Audrey L French; Michael Y Lin; Charlesnika T Evans; Lorie Benning; Marshall J Glesby; Mary A Young; Eva A Operskalski; Michael Augenbraun; Marion Peters
Journal:  Clin Infect Dis       Date:  2009-07-01       Impact factor: 9.079

Review 4.  HCV and lymphoproliferation.

Authors:  Anna Linda Zignego; Carlo Giannini; Laura Gragnani
Journal:  Clin Dev Immunol       Date:  2012-07-19

5.  Lymphocytes as liver damage mirror of HCV related adipogenesis deregulation.

Authors:  Antonella Minutolo; Beatrice Conti; Sandro Grelli; Carmela Viscomi; Giancarlo Labbadia; Clara Balsano
Journal:  PLoS One       Date:  2014-03-21       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.